TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11939813

Group type: EXPERIMENTAL
Intervention: Exotoxin reconstituted with preservative-containing saline
Number of subjects: 35

Group type: COMPARATOR
Intervention: Exotoxin reconstituted with preservative-free saline
Number of subjects: 35
Study: 9588456

Group type: EXPERIMENTAL
Intervention: Affected sib-pair linkage analysis for nephropathy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Affected sib-pair linkage analysis for retinopathy
Number of subjects: 201
Study: 8583661

Group type: EXPERIMENTAL
Intervention: Acetated Ringer (AR) solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactated Ringer (LR) solution
Number of subjects: 20
Study: 1976928

Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine
Number of subjects: 81621

Group type: COMPARATOR
Intervention: Enteric-coated capsules of Ty21a vaccine
Number of subjects: 81621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81621
Study: 90214

Group type: EXPERIMENTAL
Intervention: Methadone (average 97 mg/day, range 30-130 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (with gradual reduction of methadone at 1 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31774956

Group type: EXPERIMENTAL
Intervention: Satralizumab (120 mg, subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Satralizumab (among 55 AQP4-IgG-seropositive patients)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (among 55 AQP4-IgG-seropositive patients)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Satralizumab (among 28 AQP4-IgG-seronegative patients)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (among 28 AQP4-IgG-seronegative patients)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 27279547

Group type: EXPERIMENTAL
Intervention: AutoBT (autogenous tooth graft material)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bio-Oss® (anorganic bovine bone)
Number of subjects: 24
Study: 26349753

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23954036

Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB) depression intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 208
Study: 22888979

Group type: EXPERIMENTAL
Intervention: Home-visiting program targeting child mental health
Number of subjects: 440
Study: 18925434

Group type: EXPERIMENTAL
Intervention: Sentinel-node-based management (SNBM)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Axillary lymph-node dissection (ALND)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: SSSS arm symptoms scale
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Entire SSSS
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Single items rated by patients
Number of subjects: 643
Study: 17202432

Group type: EXPERIMENTAL
Intervention: Rotigotine (2 mg/24 h titrated to 6 mg/24 h)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 15265001

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate diet (<10% energy via carbohydrate)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fat diet (<30% energy via fat)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neither diet
Number of subjects: 15
Study: 11407200

Group type: EXPERIMENTAL
Intervention: Prospective controlled clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parallel and crossover studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open pilot studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled clinical trials
Number of subjects: 0
Study: 8980757

Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 121
Study: 7685147

Group type: EXPERIMENTAL
Intervention: FK506 at 0.05 mg/kg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FK506 at 0.10 mg/kg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FK506 at 0.15 mg/kg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FK506 at 0.20 mg/kg/day
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FK506 with dosage adjustment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: FK506 therapy
Number of subjects: 53
Study: 3553591

Group type: EXPERIMENTAL
Intervention: 10 micrograms lipo-PGE1
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 28378150

Group type: EXPERIMENTAL
Intervention: Audiovisual feedback device (TrueCPR™, Physio-Control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No feedback information
Number of subjects: 48
Study: 27387203

Group type: EXPERIMENTAL
Intervention: Walk Well intervention (12-week physical activity consultation-led walking intervention)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 102
Study: 24610884

Group type: EXPERIMENTAL
Intervention: Lower SBP target group (<130mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher SBP target group (130‐149mm Hg)
Number of subjects: 0
Study: 23609390

Group type: EXPERIMENTAL
Intervention: 300,000 IU of vitamin D (G300)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 150,000 IU of vitamin D (G150)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment (NTG)
Number of subjects: 120
Study: 20887513

Group type: EXPERIMENTAL
Intervention: Tooth Mousse® (CPP‐ACP gel; GC‐Corp, Tokyo, Japan)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fluoridin N5® (Fluoride gel; Voco‐GmbH, Cuxhaven, Germany)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study: 18712607

Group type: EXPERIMENTAL
Intervention: Culturally sensitive telephonic intervention (6 sessions of problem-focused counseling)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (8 participants)
Number of subjects: 23
Study: 15456009

Group type: EXPERIMENTAL
Intervention: Minolta VIVID 700 portable non‐contact 3D laser scanner
Number of subjects: 15

Group type: COMPARATOR
Intervention: Structured light pattern techniques (lines and dots)
Number of subjects: 15
Study: 10321135

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7642432

Group type: EXPERIMENTAL
Intervention: External radiotherapy (50 + 10 Gy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Surgery only (no radiotherapy)
Number of subjects: 101
Study: 2750356

Group type: EXPERIMENTAL
Intervention: 25 micrograms sulprostone gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 50 micrograms sulprostone gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 micrograms sulprostone gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: gel vehicle tylose
Number of subjects: 40
Study: 792490

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31226196

Group type: EXPERIMENTAL
Intervention: Ti‐reinforced dense polytetrafluoroethylene (d‐PTFE) membrane (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ti‐mesh and a cross‐linked collagen membrane (Group B)
Number of subjects: 40
Study: 28381478

Group type: EXPERIMENTAL
Intervention: Level 3 (genetic group) - FTO risk carriers (AA/AT)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Level 3 (genetic group) - FTO nonrisk carriers (TT)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Level 0 (control group)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Level 1 (dietary group)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Level 2 (phenotype group)
Number of subjects: 683
Study: 25881122

Group type: EXPERIMENTAL
Intervention: Training in shared decision making and use of a decision aid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 23592248

Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21853099

Group type: EXPERIMENTAL
Intervention: Neonatal Vitamin A Supplementation (VAS)
Number of subjects: 4345

Group type: EXPERIMENTAL
Intervention: Neonatal Vitamin A Supplementation (VAS) in girls
Number of subjects: 4345

Group type: EXPERIMENTAL
Intervention: Neonatal Vitamin A Supplementation (VAS) with FU-VAS in girls
Number of subjects: 4345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4345
Study: 19207759

Group type: COMPARATOR
Intervention: PVI
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: PVI + CFAE
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: CFAE ablation after PVI
Number of subjects: 98
Study: 17156852

Group type: EXPERIMENTAL
Intervention: Intervention utilized in the primary care trial (specific details not provided)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Poor medication adherence in the 30 days prior to the trial
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Lower self-efficacy to manage depression
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Higher scores on the Child Trauma Questionnaire
Number of subjects: 386
Study: 15114308

Group type: EXPERIMENTAL
Intervention: Endoscopic measurement of length
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Measurements by different endoscopists
Number of subjects: 12
Study: 11207014

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at 40% of maximal static inspiratory pressure (Pimax) for 20 min a day, 5 days a week for 6 weeks.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham training at a load of 10% of Pimax for 20 min a day, 5 days a week for 6 weeks.
Number of subjects: 16
Study: 9042987

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg daily (for unhealed or symptomatic patients at week 4)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 105
Study: 7940140

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low tension glaucoma group (LTG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy subjects) at IOP increment of 5 mmHg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low tension glaucoma group (LTG) at IOP increment of 5 mmHg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (healthy subjects) at IOP increment of 10 mmHg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low tension glaucoma group (LTG) at IOP increment of 10 mmHg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups at IOP increments of 5 or 10 mmHg
Number of subjects: 45
Study: 2853297

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31614418

Group type: EXPERIMENTAL
Intervention: High-amylose maize starch (HMS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Native banana starch (NBS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Digestible maize starch (DMS)
Number of subjects: 14
Study: 28549870

Group type: EXPERIMENTAL
Intervention: Mammography + quantitative transmission ultrasound
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Confidence scores from readers
Number of subjects: 37
Study: 26089641

Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 8 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 16 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 32 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 64 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Carvedilol sustained-release (SR) formulation 128 mg
Number of subjects: 31
Study: 24238498

Group type: EXPERIMENTAL
Intervention: Changfu dialysis solution 6 L
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baxter dialysis solution 6 L
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Changfu dialysis solution 8 L
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baxter dialysis solution 8 L
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Changfu 6 L vs 8 L
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Changfu before technology optimization
Number of subjects: 4
Study: 21664515

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 20 mcg/drospirenone 3 mg 24/4
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 19933719

Group type: EXPERIMENTAL
Intervention: Lithium treatment (low to moderate doses)
Number of subjects: 284
Study: 17300962

Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 14732655

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate PDT
Number of subjects: 101

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 101
Study: 11570022

Group type: EXPERIMENTAL
Intervention: Telephone reminder
Number of subjects: 1908

Group type: EXPERIMENTAL
Intervention: Mail reminder
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Routine publicity
Number of subjects: 1908
Study: 9782690

Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions for patients with hypertension
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions for patients with COPD
Number of subjects: 231
Study: 7945575

Group type: EXPERIMENTAL
Intervention: CAGE questionnaire
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Plasma levels of acetate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Mean corpuscular volume (MCV)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Gamma glutamyl transferase (GGT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Glycosylated haemoglobin (Hb A1c)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combination of CAGE questionnaire and other tests
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Objective variables (MCV, acetate, GGT)
Number of subjects: 121
Study: 3075425

Group type: EXPERIMENTAL
Intervention: TCu340 IUD
Number of subjects: 431

Group type: COMPARATOR
Intervention: MLCu375
Number of subjects: 431

Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 431
Study: 29728515

Group type: EXPERIMENTAL
Intervention: Interim PET (I-PET)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: End-of-Treatment PET (EoT-PET)
Number of subjects: 465
Study: 27519791

Group type: EXPERIMENTAL
Intervention: PNA clamping-assisted fluorescence melting curve analysis for EGFR mutations
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: PNA clamping-assisted fluorescence melting curve analysis for KRAS mutations
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Plasma mutation status
Number of subjects: 194
Study: 26715701

Group type: EXPERIMENTAL
Intervention: Epidural infusion analgesia
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intra-articular infusion analgesia
Number of subjects: 75
Study: 23561916

Group type: EXPERIMENTAL
Intervention: Muscle relaxants and celecoxib
Number of subjects: 150

Group type: COMPARATOR
Intervention: Muscle relaxants alone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 20628590

Group type: EXPERIMENTAL
Intervention: ACEi (Trandolapril 2 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-ACEi therapy
Number of subjects: 90
Study: 19041835

Group type: EXPERIMENTAL
Intervention: Eplerenone with standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0
Study: 16439590

Group type: EXPERIMENTAL
Intervention: HiPro formula (3.6 g/100 kcal)
Number of subjects: 18

Group type: COMPARATOR
Intervention: RegPro formula (3.0 g/100 kcal)
Number of subjects: 18
Study: 12910587

Group type: EXPERIMENTAL
Intervention: Infant Flow VF‐NCPAP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Arabella VF‐NCPAP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both VF‐NCPAP devices
Number of subjects: 18
Study: 10975587

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 26
Study: 8885035

Group type: EXPERIMENTAL
Intervention: 5-week rehabilitation programme
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 14
Study: 1393157

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Behaviour therapy (exposure and response prevention)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 38
Study: 3900907

Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract administered at birth
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 32
Study: 30358737

Group type: EXPERIMENTAL
Intervention: Breast-fed infants with different metabolite clusters
Number of subjects: 183
Study: 29100885

Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide (CO) at 100 to 200 parts per million for 2 hours daily, twice weekly, for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Inhaled 21% oxygen (placebo) for 2 hours daily, twice weekly, for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Inhaled carbon monoxide (CO)
Number of subjects: 58
Study: 26471344

Group type: EXPERIMENTAL
Intervention: High protein diet (HP; 1.7 g kg(‐1) per day; n=31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal protein diet (NP; 0.9 g kg(‐1) per day; n=30)
Number of subjects: 61
Study: 24708516

Group type: EXPERIMENTAL
Intervention: Shaker exercise once a day for 6 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Shaker exercise three times a day for 6 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Follow-up after 4 weeks post-exercise
Number of subjects: 19
Study: 23234151

Group type: EXPERIMENTAL
Intervention: Jianpi Huatan Fang
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin E Recipe
Number of subjects: 60
Study: 20492037

Group type: EXPERIMENTAL
Intervention: Tai Chi programme (26 weeks)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Normal daily activities (Control group)
Number of subjects: 139
Study: 18936502

Group type: EXPERIMENTAL
Intervention: Nurse-led disease management intervention (12-month program with 1 face-to-face encounter and regular telephone follow-up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-led disease management intervention (sensitivity analysis)
Number of subjects: 0
Study: 15860509

Group type: EXPERIMENTAL
Intervention: Etanercept/methotrexate combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study: 12824094

Group type: EXPERIMENTAL
Intervention: Theaflavin-enriched green tea extract (375 mg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 10638896

Group type: EXPERIMENTAL
Intervention: Mivacurium (0.2 mg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 23
Study: 8797123

Group type: EXPERIMENTAL
Intervention: Radiographically defined vertebral deformity
Number of subjects: 15570

Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 15570

Group type: EXPERIMENTAL
Intervention: Geographical variation
Number of subjects: 15570
Study: 1536481

Group type: EXPERIMENTAL
Intervention: Diphenhydramine plus placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cimetidine plus placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diphenhydramine plus cimetidine
Number of subjects: 39
Study: 6321689

Group type: EXPERIMENTAL
Intervention: FACP/weekly doxorubicin
Number of subjects: 100

Group type: COMPARATOR
Intervention: FACP/standard doxorubicin
Number of subjects: 100
Study: 31513144

Group type: EXPERIMENTAL
Intervention: Manual toothbrush Curaprox CS 5460 together with single‐tufted brush Curaprox CS 1006
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual toothbrush Curaprox CS 5460
Number of subjects: 30
Study: 30099212

Group type: EXPERIMENTAL
Intervention: NLC with higher MAPL content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NLC with lower MAPL content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nano-sized emulsions with increased oil phase volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NLC-based formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emulsion
Number of subjects: 0
Study: 27042735

Group type: EXPERIMENTAL
Intervention: Seasonal inactivated influenza vaccine without a lipid adjuvant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24796768

Group type: EXPERIMENTAL
Intervention: 0.8 g LT‐02
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 1.6 g LT‐02
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 3.2 g LT‐02
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 23051558

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination (T80/H25)
Number of subjects: 0